SLS vs. VTVT, ANEB, RVPH, LPTX, IFRX, AFMD, RLYB, YS, TPST, and LFVN
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include vTv Therapeutics (VTVT), Anebulo Pharmaceuticals (ANEB), Reviva Pharmaceuticals (RVPH), Leap Therapeutics (LPTX), InflaRx (IFRX), Affimed (AFMD), Rallybio (RLYB), YS Biopharma (YS), Tempest Therapeutics (TPST), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry.
vTv Therapeutics (NASDAQ:VTVT) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
In the previous week, vTv Therapeutics had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 5 mentions for vTv Therapeutics and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat vTv Therapeutics' score of -0.10 indicating that vTv Therapeutics is being referred to more favorably in the media.
vTv Therapeutics received 341 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. However, 58.82% of users gave SELLAS Life Sciences Group an outperform vote while only 57.83% of users gave vTv Therapeutics an outperform vote.
vTv Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.
SELLAS Life Sciences Group's return on equity of 0.00% beat vTv Therapeutics' return on equity.
SELLAS Life Sciences Group has a consensus target price of $3.00, indicating a potential upside of 121.40%. Given vTv Therapeutics' higher probable upside, analysts clearly believe SELLAS Life Sciences Group is more favorable than vTv Therapeutics.
vTv Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. vTv Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.7% of vTv Therapeutics shares are held by company insiders. Comparatively, 1.6% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
vTv Therapeutics beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.
Get SELLAS Life Sciences Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
